By Counterforce Health Team in Onivyde (irinotecan liposome) —

Humana's Coverage Criteria for Onivyde (Irinotecan Liposome) in New Jersey: What Counts as "Medically Necessary"?

Answer Box: Humana Onivyde Coverage in New Jersey

Onivyde (irinotecan liposome) is covered by Humana Medicare Advantage with prior authorization for FDA-approved pancreatic cancer indications. Medical necessity requires: ECOG performance status 0-1, documented diagnosis, and appropriate line of therapy (first-line NALIRIFOX or second-line post-gemcitabine). Fastest approval: Submit complete PA documentation through Humana provider portal with oncologist attestation. Start today: Contact your oncologist's prior authorization team to initiate the coverage determination request. If denied, you have 65 days to appeal through Medicare's process, plus New Jersey's IHCAP external review option.

Table of Contents

Policy Overview

Humana covers Onivyde through Medicare Part B as a physician-administered drug under HCPCS code J9205. Coverage applies across all Humana Medicare Advantage plan types—HMO, PPO, and HMO-POS—but network requirements vary.

HMO Plans: Your oncologist must be in-network, and you may need a referral from your primary care physician. Out-of-network treatment typically isn't covered except in emergencies.

PPO Plans: You can see out-of-network providers, but you'll pay significantly higher cost-sharing (often 40-50% instead of 20%).

Note: Humana's 2025 Medicare Prior Authorization List confirms that prior authorization is required for all Onivyde regimens.

FDA-Approved Indications

Humana covers Onivyde for two specific clinical scenarios that meet FDA labeling:

First-Line Metastatic Pancreatic Adenocarcinoma

The NALIRIFOX regimen (Onivyde + oxaliplatin + 5-FU + leucovorin) received FDA approval in February 2024 based on the NAPOLI-3 trial. This combination showed superior overall survival compared to nab-paclitaxel plus gemcitabine (11.1 vs. 9.2 months).

Second-Line Treatment Post-Gemcitabine

Onivyde combined with 5-FU and leucovorin is approved for patients whose disease progressed following gemcitabine-based therapy. This indication is based on the NAPOLI-1 trial data.

Off-Label Use: Coverage for indications outside FDA labeling requires additional justification and may face higher denial rates. You'll need compelling clinical evidence and guideline support.

Step Therapy Requirements

As of 2025, Humana's Part B Step Therapy Preferred Drug List classifies Onivyde as non-preferred, which may trigger step therapy requirements.

Potential Step Therapy Agents:

  • Standard irinotecan (J9206)
  • Other preferred chemotherapy regimens for pancreatic cancer

Medical Exception Pathways:

  • Contraindication to preferred agents
  • Previous failure or intolerance
  • Clinical superiority of Onivyde for your specific case

Document any prior treatment failures with specific dates, reasons for discontinuation, and clinical outcomes.

Quantity and Frequency Limits

Humana imposes specific quantity limits aligned with FDA labeling:

Dosing Schedule Maximum Per Cycle Billing Code
Standard dosing 172 mg every 14 days J9205
UGT1A1*28 reduced dose 125 mg every 14 days (initial) J9205
Duration limit 6 months initial approval Renewal required

Dose Adjustments: If you're homozygous for UGT1A1*28 allele, Humana recognizes the need for dose reduction. Include genetic testing results in your PA submission.

Renewal Requirements: After 6 months, your oncologist must document treatment response and continued medical necessity for coverage continuation.

Required Clinical Documentation

Your prior authorization must include comprehensive clinical evidence:

Essential Documentation Checklist

  • Patient demographics and Humana member ID
  • Diagnosis with ICD-10 codes (C25.0-C25.9 for pancreatic cancer)
  • ECOG performance status (must be 0-1 for coverage)
  • Prior therapy history with specific agents, dates, and outcomes
  • Planned treatment regimen including cycle count and duration
  • Clinical rationale with supporting literature

Laboratory Requirements

  • Recent comprehensive metabolic panel
  • Complete blood count with differential
  • Liver function tests (especially important for irinotecan)
  • UGT1A1 genetic testing (if applicable)
Tip: Submit lab results within 30 days of the PA request for fastest processing.

Site of Care Requirements

Onivyde is administered only in qualified clinical settings:

Approved Sites:

  • Hospital outpatient infusion centers
  • Oncology clinics with infusion capabilities
  • Ambulatory surgical centers

Network Requirements: For HMO plans, verify that your chosen infusion site is in Humana's network before treatment begins. PPO plans offer more flexibility but at higher cost-sharing.

The medication is not dispensed through specialty pharmacies—it's a buy-and-bill drug purchased by your treatment facility.

Evidence Supporting Medical Necessity

Strong medical necessity documentation should reference established clinical guidelines and peer-reviewed evidence:

Key Clinical References

  • NCCN Guidelines: Onivyde-containing regimens are Category 1 recommendations for appropriate indications
  • FDA Label: Reference specific indications and dosing from the official prescribing information
  • NAPOLI Trials: Cite efficacy data from NAPOLI-1 (second-line) and NAPOLI-3 (first-line) studies

Supporting Your Case

Include 2-3 relevant citations in your medical necessity letter. Focus on guidelines that specifically mention your patient's clinical scenario.

Sample Medical Necessity Narrative

Here's a template structure for your oncologist's medical necessity letter:

"[Patient name] is a [age]-year-old with metastatic pancreatic adenocarcinoma (ICD-10: C25.9) and ECOG performance status [0/1]. [He/She] is appropriate for [first-line NALIRIFOX/second-line post-gemcitabine] treatment per NCCN guidelines. Prior therapy included [specific agents and outcomes]. Onivyde is medically necessary because [specific clinical rationale]. The requested regimen aligns with FDA labeling and published efficacy data from [NAPOLI-1/NAPOLI-3]. Patient meets all clinical criteria including adequate performance status and organ function."

Common Denial Reasons & Solutions

Denial Reason Solution Strategy
"Not medically necessary" Submit detailed clinical rationale with guideline citations
Step therapy not completed Document contraindications or prior failures of preferred agents
Incorrect dosing/frequency Reference FDA label for standard dosing parameters
Missing lab values Provide recent CBC, CMP, and liver function tests
Performance status unclear Document ECOG status with clinical assessment
Off-label use Include compelling clinical evidence and expert guidelines

Appeals Process in New Jersey

If Humana denies your Onivyde coverage, you have multiple appeal options:

Internal Appeals (Medicare Process)

  • Timeline: 65 days from denial to file
  • Standard Review: 30 days for coverage determination
  • Expedited Review: 72 hours for urgent cases
  • Submission: Humana member portal or written request

New Jersey External Review (IHCAP)

After completing Humana's internal appeals, you can request external review through New Jersey's Independent Health Care Appeals Program:

  • Administrator: Maximus Federal Services
  • Timeline: 4 months from final denial to file
  • Success Rate: Approximately 40-50% for oncology drug appeals
  • Cost: Free to patients
  • Contact: 1-888-866-6205 or njihcap.maximus.com
From our advocates: "We've seen New Jersey external reviews succeed when the oncologist submits a detailed letter explaining why Onivyde is the most appropriate treatment option, especially when standard therapies have failed or are contraindicated. The key is comprehensive clinical documentation that addresses the specific denial reason."

Required Appeal Documentation

  • Copy of original denial letter
  • Complete medical records
  • Oncologist's detailed medical necessity letter
  • Relevant clinical studies or guidelines
  • Patient authorization forms

FAQ

How long does Humana prior authorization take for Onivyde in New Jersey? Standard PA decisions take 1-2 weeks with complete documentation. Expedited review is available within 72 hours for urgent medical situations.

What if Onivyde isn't on Humana's formulary? Onivyde is typically covered under Medicare Part B (not Part D formulary). Coverage depends on medical necessity and FDA-approved indications rather than formulary placement.

Can I get expedited approval for Onivyde? Yes, if your oncologist documents that delay would cause serious harm to your health. Submit an expedited PA request with clinical justification.

Does step therapy apply if I tried other treatments outside New Jersey? Yes, document all prior therapies regardless of where you received them. Include treatment dates, outcomes, and reasons for discontinuation.

What's my cost-sharing for Onivyde with Humana? Typically 20% coinsurance after your Part B deductible ($240 in 2025). Exact costs vary by specific plan.

How do I find an in-network oncologist for HMO plans? Use Humana's provider directory at Humana.com or call member services at the number on your insurance card.

About Counterforce Health: Counterforce Health helps patients and clinicians navigate complex prior authorization and appeals processes for specialty medications like Onivyde. Our platform analyzes denial letters and generates targeted, evidence-backed appeals that address payer-specific requirements and clinical guidelines.

When facing insurance denials, having expert support can significantly improve your chances of approval. Counterforce Health specializes in turning denials into successful appeals by identifying the specific basis for denial and crafting point-by-point rebuttals with the right clinical evidence.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on your specific plan and clinical circumstances. Always consult with your healthcare provider and insurance plan for personalized guidance. For assistance with New Jersey insurance issues, contact the NJ Department of Banking and Insurance at 1-800-446-7467.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.